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Abstract
Background: Procedures that may optimize success in achieving live births from assisted reproductive technology
(ART) continue to be examined. Not yet considered are the perspectives of fertility specialists regarding important
developments in the fertility treatment field, current unmet needs, and anticipated future advances. In the current
study, an 8-country survey of fertility specialists was conducted to provide a comprehensive, global depiction of
fertility treatments across different regions.
Methods: Fertility specialists from France, Germany, Italy, Spain, the United Kingdom (UK), the United States (US),
China, and Japan were invited to participate in an online survey. Participants were eligible if they personally
managed ≥25 patients/month who were experiencing difficulty conceiving, and if they had performed ART fertility
treatment with ≥1 patient in the previous month. Quantitative questions addressed the number of patients seen,
main infertility causes, number of cycles performed, ART procedure type, and ART outcomes. Qualitative questions
covered diagnostic trends, unmet needs, important advances, and expected future developments.
Results: The number of fertility specialists who completed the survey included 29 in France, 33 in Germany, 23 in
Italy, 38 in Spain, 34 in the UK, 91 in the US, 50 in China, and 65 in Japan. Patient volume increased over the prior
2 years according to 67 % (242/363) of the fertility specialists. As expected, ART outcomes all declined with age
in all countries. ART outcomes varied by country, with the highest implantation, pregnancy, and live birth rates
reported by fertility specialists in the US and China and the lowest rates reported in France and Italy. The most
frequently reported unmet needs in fertility treatment were financial coverage, improved implantation rate, and
egg donation. Most frequently named future advancements expected to change the fertility treatment field
included improved embryo selection through imaging and/or metabolomics, improved embryo implantation rate,
and use of preimplantation genetic diagnosis.
Conclusions: This study, which follows a rigorous survey methodology, elucidates the current state of fertility
specialists’ practices and perspectives on the global fertility treatment field, which highlights differences and
similarities among countries. This research may inform further studies and procedural developments that might
better improve and standardize ART.
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Background
Considerable progress continues to be made in assisted
reproductive technology (ART) fertility treatment since
the birth of the first “test tube baby”, Louise Brown, in
1978 in the United Kingdom (UK), followed by other live
births in Australia (1980), the United States (US) (1981),
and in Sweden and France (1982) [1, 2]. However, fertil-
ity treatment remains a complex field that involves many
different dimensions over the course of patient treat-
ment, such as hormonal treatment to produce eggs, re-
trieval of eggs and sperm, varied fertilization techniques,
such as in vitro fertilization (IVF), intracytoplasmic
sperm injection (ICSI) and intracytoplasmic morpho-
logically selected sperm injection (IMSI), use of one’s
own or donor eggs, fresh versus frozen embryos, number
of embryos to transfer, and preimplantation genetic
diagnosis (PGD) [2]. Additionally, variations in fertility
treatment exist among countries, such as illegality of
donor IVF cycles in Germany; illegality of PGD and pre-
implantation genetic screening (PGS) in France; and
illegality of embryo storage in Italy until 2009, mandating
a requirement that all generated embryos be implanted.
Fertility specialists are continually examining ways to
optimize the techniques and processes within the fertil-
ity treatment field to improve success in achieving live
births. Recent targets of interest have included analyzing
procedures for ovulation induction and triggering final
oocyte maturation [3–6], improving the prediction of
ovarian response to stimulation [7, 8], determining opti-
mal duration of co-incubation of gametes [9], assessing
endometrial receptivity and implications for the use of
fresh versus frozen embryos [10, 11], examining embryo
culture techniques [12], monitoring embryo development
through new techniques such as time-lapse embryo moni-
toring [13], and improving embryo selection for transfer
[14]. Despite numerous improvements in fertility treat-
ment, the number of factors that have an impact on fertil-
ity make fertility difficult to control and the desired
outcome of a live birth cannot be guaranteed. Fertility
specialists are continuously looking for ways to improve
pregnancy rate (PR) and live birth rate (LBR) in patients.
Large ART fertility treatment registries exist through
the European IVF Monitoring Consortium on behalf of
the European Society of Human Reproduction and Em-
bryology (ESHRE) in Europe [15] and the Centers for
Disease Control and Prevention (CDC) in the US [16].
Although the registries provide comprehensive data on
the current state of ART in Europe and the US, they
have some important limitations. The registry reports
are published with some delays, with the currently avail-
able publications reporting 2010 data in Europe, and
2012 data in the US. Additionally, the registry reports
are based exclusively on quantitative data. There are no
known publically available qualitative data describing the
perceptions of fertility specialists regarding current un-
met needs or the important developments in the field of
fertility treatment. For the ESHRE report, the method of
reporting data to the registry is not standardized and con-
sequently there is variability among countries in the infor-
mation reported.
ART, and more specifically IVF, continues to change
and further develop with new technologies. However,
many questions remain, including: What have been the
true innovations in the field of fertility treatment, and
how have they affected the treatment of patients? What
are the differences per country in fertility treatment?
Where are fertility treatments headed in the future?
In the current study, an 8-country survey of fertility
specialists was conducted with the aim to provide a
comprehensive depiction of fertility treatments across
different regions. Using a standardized survey-based ap-
proach, the goal of the research was to provide both quan-
titative data and qualitative perceptions from fertility
specialists regarding which developments have been
most important in the field of fertility treatment within
the past 30 years, the current unmet needs in fertility
treatment, and which anticipated improvements will be
“game changers” in fertility specialty practices in the
coming years.
Methods
Study participants and design
Fertility specialists from the European Union Five (EU5,
which includes France, Germany, Italy, Spain, and the
UK), the US, China, and Japan were invited to partici-
pate in an online survey aimed at understanding current
management of women experiencing difficulty conceiv-
ing. The criteria for the selection of these countries
included having a high number of patients who undergo
ART, the representation of a broad spectrum of fertility
treatment regulations and practices across the included
countries, and high access to the internet within each
country. In the EU5 and US, a sample frame of 3975
fertility specialists was established by assembling physi-
cians from public sources, such as the ESHRE annual
ART reports and the CDC web site, that list fertility
clinics [17]. For China and Japan, no lists of fertility
clinics were found. For that reason, an external panel
provider, M3, was used. M3 had access to 39,930 endo-
crinologists, obstetricians/gynecologists, embryologists,
and reproductive health specialists in China and 11,366
in Japan. Practice specialty was self-referenced by sur-
vey respondents, but did not include the fertility
specialization, which was why the sample frame of physi-
cians in China and Japan was larger than in the other
participating countries. In China and Japan, the verifica-
tion of a participant’s fertility specialist credentials was
achieved through the eligibility screening criteria of the
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study. The physician sample was randomized and no other
factors applied to influence completion patterns. In the
EU5 and US, all 3975 fertility specialists contained within
the sample frame were invited to participate in the survey
by e-mail or postal mail. In China and Japan, endocrinolo-
gists, obstetricians/gynecologists, embryologists, and re-
productive health specialists were invited by e-mail only.
Fertility specialists were eligible to participate if they
personally managed ≥25 patients per month who were
experiencing difficulty conceiving, and if they had per-
formed ART with ≥1 patient in the previous month.
Participants were offered an industry-standard honorar-
ium as compensation for their time in completing the
survey. The survey was administered online and was
fielded from March 26, 2015, to May 26, 2015. By opting
into to the survey, respondents provided consent to use
their anonymous responses to the survey questions.
Because this study did not involve patients or patient data,
Institutional Review Board approval and patient consent
were not required.
Fertility treatment physician practice survey
A survey was developed to assess current fertility treat-
ment practices, with a focus on ART procedures. The
survey was pre-tested through interviews and consulta-
tions with 33 fertility specialists throughout 21 countries.
The online questionnaire used in the current study
included both quantitative and qualitative questions.
Quantitative questions covered the following topics:
the number of patients having difficulty conceiving;
the main causes for fertility issues; and for each age
group split, the number of cycles performed, the type
of ART procedure used, and the ART treatment out-
comes. ART treatment outcomes were assessed using
4 outcome metrics: the proportion of cycles for which
an embryo reached the developmental stage sufficient
for the embryo to be transferred, the implantation rate,
the proportion of cycles that resulted in pregnancy (i.e.,
PR) and the proportion of cycles that resulted in a live
birth (i.e., LBR). Qualitative questions covered trends in
diagnosis, unmet needs in the field of fertility treatment,
the perceived biggest improvement in fertility treatment
in the past 30 years, and expected development(s) that
could be the next “game changer” in fertility treatment.
All respondents provided qualitative comments because
these sections of the survey were mandatory.
Data analysis
All survey data were analyzed in aggregate and the
individual identities of the survey respondents were
blinded to the study authors. The planned analyses
for quantitative data were descriptive and included
means and percentages. Qualitative data were analyzed
thematically and coded according to the main themes of
the survey questions. Any response that addressed mul-
tiple themes was counted as multiple comments.
Results
A total of 1435 physicians responded to the survey
invitation and 363 met eligibility criteria and completed
the survey. The number of respondents by country who
completed the survey included 157 fertility specialists in
the EU5 (29 in France, 33 in Germany, 23 in Italy, 38 in
Spain, and 34 in the UK), 91 in the US, 50 in China, and
65 in Japan.
Physicians’ practice
The mean number of women with difficulty conceiving
seen per month ranged from 63 in Italy to 236 in China
(Table 1). In terms of age split, patients >42 years old
represented the lowest proportion of patients seen in all
countries, with the exception of Spain, ranging from 6 %
in France to 15 % in Italy. In Spain, the lowest propor-
tion of patients seen was within the youngest category of
age <35 years old (10 %) followed by patients >42 years
old (11 %), and the highest proportion of patients
seen occurred in the age category of 35 to 39 years
old (63 %).
The main causes for the difficulty conceiving were very
similar across all countries, with male factor, both male
and female factor, diminished ovarian reserve, and ovula-
tory dysfunction being the most frequently reported
causes of infertility (Table 2). The only meaningful dif-
ference among countries was the report of tubal factor
as the infertility cause in 36 % of women in China,
whereas tubal factor was reported as ≤16 % in all other
countries.
Among the categories of fertility management, ART
use was highest in the EU5, ranging from 47 % of fertil-
ity specialists in France to 75 % in Spain, compared with
37 % in the US, 38 % in China, and 27 % in Japan
(Table 3). Intrauterine insemination/ovulation induction
was reported most frequently by fertility specialists in
the US (35 %). Use of the drug clomiphene was highest
in China and Japan, reported by 22 and 23 % of fertility
specialists, respectively, and ranged from 2 % (Spain) to
14 % (US) of fertility specialists in the other countries.
Patient volume
The number of women who consulted for issues related
to difficulty conceiving increased over the prior 2 years
according to 67 % (242/363) of the fertility specialists.
The percentage of survey respondents who reported an
increase in patient volume ranged from 49 % in the US
to 85 % in Germany and 94 % in China (Fig. 1). Fertility
specialists in France, Germany, Italy, Spain and Japan
most frequently reported the aging population as the
reason for the increase in patient volume. In the UK and
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the US, survey respondents reported the increase in
patient volume was driven by increased referrals and
improved access to IVF centers. Fertility specialists in
China reported an increased number of infertility cases
due to pollution, irradiation, and/or lifestyle habits. A
decrease in the number of women who consulted for
issues related to difficulty conceiving was reported in
Italy, Spain, the US, and Japan by 6.9 % (25/363) of the
fertility specialists. Respondents from Italy and Spain
reported the decrease was due to the economic crisis. In
the US and Japan, the decrease was reported as being
due to increased availability of clinics providing fertil-
ity services and a reduction in financial coverage for
patients.
Current ART practice
The mean number of ART procedures performed per
year greatly varied across countries. The fertility special-
ists based in Japan, Italy, and the US had the lowest
mean number of ART procedures at 170, 242, and 253
per year, respectively, followed by fertility specialists
based in Spain (341 procedures), France (353), Germany
(462) and the UK (492). Fertility specialists based in
China had the highest mean number of ART procedures
per year at 894. The proportion of ART procedures
performed by age group is shown in Fig. 2. A high pro-
portion of ART procedures were done for patients
<35 years old in China (53 %), whereas a low proportion
of ART procedures were done for patients <35 years old
in Spain (16 %). The majority of patients completed 1 to
3 ART cycles with a slight trend toward more ART
cycles as patient age increased (Table 4).
Survey respondents reported the percentage of their
patients who received ICSI, fresh embryo, and donor
embryo ART cycles (Table 5). ICSI was most frequently
performed in Spain, Italy, Germany, France, and the US
where it was used in 55 to 89 % of cycles. ICSI was used
slightly less frequently by fertility specialists based in
the UK, China, and Japan, ranging from 35 to 56 %
of ART cycles. With the exception of Italy, all
Table 1 Women seen per month by fertility specialists by country and age group
Percentage of women by age group
Number of women (Mean) <35 y 35 to 39 y 40 to 42 y >42 y
France n = 29 82.4 37 % 37 % 20 % 6 %
Germany n = 33 175.9 26 % 50 % 16 % 9 %
Italy n = 23 62.6 18 % 43 % 24 % 15 %
Spain n = 38 118.8 10 % 63 % 17 % 11 %
UK n = 34 75.8 30 % 39 % 19 % 12 %
US n = 91 145.3 37 % 33 % 21 % 9 %
China n = 50 235.8 46 % 32 % 14 % 8 %
Japan n = 65 145.4 29 % 39 % 24 % 9 %
UK United Kingdom, US United States, Y years
Table 2 The percentage of fertility specialists reporting the cause of infertility by country
Causes of infertility France Germany Italy Spain UK US China Japan
n = 29 n = 33 n = 23 n = 38 n = 34 n = 91 n = 50 n = 65
Male factor 27 % 31 % 22 % 24 % 26 % 24 % 20 % 22 %
Female and male factor 25 % 27 % 21 % 29 % 20 % 21 % 17 % 19 %
Diminished ovarian reserve 17 % 16 % 24 % 28 % 17 % 22 % 11 % 18 %
Ovulatory dysfunction 21 % 17 % 14 % 11 % 17 % 23 % 20 % 25 %
Tubal factor 11 % 13 % 11 % 7 % 13 % 11 % 36 % 16 %
Multiple female factor 15 % 17 % 10 % 13 % 10 % 16 % 14 % 19 %
Unknown 13 % 9 % 13 % 13 % 21 % 12 % 6 % 24 %
Endometriosis 11 % 13 % 10 % 13 % 10 % 11 % 15 % 15 %
Uterine factor 5 % 5 % 4 % 5 % 5 % 5 % 10 % 6 %
Stress/Psychological factor 4 % 3 % 3 % 4 % 4 % 2 % 7 % 7 %
Other 3 % 3 % 1 % 2 % 2 % 1 % 4 % 1 %
UK United Kingdom, US United States
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countries showed an increase in the frequency of ICSI
cycles with increased patient age. Fresh embryos were
largely used by fertility specialists based in France,
Germany, and Italy, ranging from 65 to 94 % of ART
cycles. In these countries, the use of fresh embryos
increased with increased patient age. Among fertility
specialists based in Spain, the UK, and the US, there
was little variation in the use of fresh embryos by
patient age group. Use of fresh embryos fluctuated
between 68 to 75 % in Spain, 72 to 83 % in the UK,
and 67 to 73 % in the US across patient age groups.
In China, the opposite trend was reported with the
use of fresh embryos decreasing with increased patient
age, ranging from 58 % for patients <35 years old to 38 %
for patients >42 years old. Fertility specialists based in
Japan reported the lowest use of fresh embryos at 36 to
46 % of patients, with little variation by patient age group.
Reported use of donor eggs in ART cycles was very limited
in France, Italy, and Japan (≤18 %) with no such reports
from survey respondents in Germany because use of
donor eggs is illegal in that country. Survey participants
based in China used donor eggs in 10 to 20 % of ART cy-
cles. Fertility specialists based in the US and UK reported
similar use of donor eggs in ART cycles, ranging from 7
and 9 % for patients <35 years old to 45 % and 46 % for
patients >42 years old, respectively. Fertility specialists
based in Spain reported the most frequent use of donor
eggs, ranging from 11 % for patients <35 years old to 58 %
for patients >42 years old.
The number of embryos, categorized as single embryo
transfer (SET), dual embryo transfer (DET), and >2 em-
bryos transferred (>DET) back to the patient at each
ART cycle increased with increased patient age (Table 6).
The majority of patients <35 years old received SET or
DET across all countries. Among patients >42 years old,
41 % of patients in the US received > DET, 30 % of pa-
tients in Italy received > DET, and 17 to 18 % of patients
in France, Germany, and the UK received > DET. In
China, Spain, and Japan, ≤9 % of patients >42 years old
received > DET.
Table 3 Percentage of fertility specialists reporting use of fertility management treatments
Fertility management types France Germany Italy Spain UK US China Japan
n = 29 n = 33 n = 23 n = 38 n = 34 n = 91 n = 50 n = 65
IUI/OI 27 % 19 % 22 % 16 % 11 % 35 % 14 % 27 %
ART 47 % 49 % 56 % 75 % 59 % 37 % 38 % 27 %
Clomiphene 6 % 13 % 7 % 2 % 10 % 14 % 22 % 23 %
Watch and wait 10 % 7 % 9 % 4 % 12 % 4 % 15 % 14 %
Surgery 9 % 9 % 5 % 3 % 7 % 8 % 9 % 4 %
Other 1 % 3 % 0 % 0 % 1 % 2 % 2 % 4 %
ART assisted reproductive technology, IUI/OI intrauterine insemination/ovulation induction UK United Kingdom, US United States
Fig. 1 Trends in fertility specialist patient volume. Trends in fertility specialist patient volume are shown by country for women with difficulty
conceiving over the prior 2-year period. The percentage of fertility specialist respondents who reported an increased volume, steady volume, or
decreased volume is shown within the bars of the figure. UK, United Kingdom; US, United States
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ART procedure outcomes
All 4 ART procedure outcome measures, including per-
centage of patients with implantable embryos, implantation
rate, PR, and LBR, declined with age in all countries
(Figs. 3, 4, 5 and 6). The percentage of patients with
implantable embryos was similar across all countries and
ranged from an average of 85 % for patients <35 years old
to 51 % for patients >42 years old (Fig. 3). Among patients
<35 years old, the fertility specialists based in China
reported the highest implantation rate (54 %), while the
lowest implantation rates were reported by specialists
based in Italy and France (33 and 35 %, respectively)
(Fig. 4). The implantation rate among patients >42 years
old ranged from 9 % of patients in Italy to 25 % of patients
in Spain and 27 % of patients in China. Among patients
<35 years old, the reported PR ranged from 33 % of
patients in France to 53 % of patients in China and 54 % in
the US (Fig. 5). For patients >42 years old, the PR ranged
from 9 % of patients in France and Japan to 26 % of pa-
tients in Spain. The lowest LBR among patients <35 years
old was reported by fertility specialists in France at 27 % of
patients (Fig. 6). Specialists in China and the US reported
an LBR of 47 and 48 %, respectively, in this patient age
group. For patients >42 years old, the reported LBR ranged
from 4 to 6 % of patients in Japan, France, and Germany,
up to 19 % of patients in Spain, and 21 % in China.
Fig. 2 The proportion of patients who received ART procedures by age group. Fertility specialists reported the percentage of their patients who
received ART procedures across the patient age groups <35 years old, 35 to 39 years old, 40 to 42 years old, and >42 years old. The percentages
are shown by country and by age within the bars of the figure. ART, assisted reproductive technology; UK, United Kingdom; US, United States
Table 4 Percentage of patients who received from 1 to >3 ART cycles by patient age group
<35 years old 35 to 39 years old 40 to 42 years old >42 years old
ART cycles ART cycles ART cycles ART cycles
1 2 3 >3 1 2 3 >3 1 2 3 >3 1 2 3 >3
France n = 29 36 % 27 % 20 % 18 % 34 % 28 % 21 % 17 % 36 % 29 % 19 % 16 % 40 % 22 % 16 % 22 %
Germany n = 33 38 % 36 % 18 % 9 % 24 % 37 % 27 % 12 % 18 % 29 % 24 % 28 % 21 % 28 % 37 % 15 %
Italy n = 23 54 % 26 % 15 % 4 % 33 % 44 % 18 % 5 % 28 % 46 % 17 % 8 % 32 % 45 % 11 % 12 %
Spain n = 38 59 % 24 % 11 % 6 % 54 % 25 % 12 % 9 % 46 % 32 % 14 % 8 % 50 % 33 % 11 % 6 %
UK n = 34 53 % 28 % 13 % 6 % 46 % 32 % 14 % 8 % 42 % 32 % 16 % 10 % 49 % 28 % 16 % 7 %
US n = 91 57 % 26 % 13 % 4 % 44 % 32 % 19 % 5 % 35 % 31 % 21 % 13 % 40 % 28 % 21 % 11 %
China n = 50 57 % 26 % 12 % 6 % 39 % 32 % 18 % 11 % 26 % 29 % 23 % 22 % 25 % 26 % 26 % 23 %
Japan n = 65 33 % 28 % 20 % 20 % 27 % 26 % 26 % 22 % 23 % 24 % 23 % 30 % 24 % 21 % 18 % 37 %
ART assisted reproductive technology, UK United Kingdom, US United States
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Important improvements in fertility treatments
Survey participants identified what they perceived to be
the greatest improvements in the field of fertility treat-
ment within the past 30 years. The relative rankings of
the improvements varied by country. However, improve-
ments that were most frequently cited included ICSI
(ranging from 14 % of respondents in Japan to 83 % in
France), vitrification and cryopreservation techniques
that provide the ability to freeze gametes and embryos
(ranging from 16 % of respondents in China to 66 % in
Spain), improvement in hormonal drugs and treatment
protocols (ranging from 18 % of respondents in China to
39 % in Germany), and the ability to culture embryos up
to the blastocyst stage (ranging from 15 % of respon-
dents in Japan to 41 % in the UK) (Fig. 7). PGD was
mentioned as a major improvement by fertility special-
ists in only 3 countries: the US (43 %), Spain (26 %),
and China (34 %). Less frequently reported across all
countries was the development of ART itself (22 % of
respondents in Japan and 40 % of respondents in
China) and SET (14 % of respondents in Japan).
Unmet needs and expected advancements in fertility
treatment
Fertility specialists reported current unmet needs for
patients who have difficulty conceiving and choose to
pursue fertility treatment. Among the most frequently
reported unmet needs, better financial coverage was
mentioned by survey respondents from all countries but
France, ranging from 17 % of survey respondents in Italy
to 67 % in the US (Fig. 8). With the exception of China,
improvement in implantation rate was reported as an
important unmet need by fertility specialists from all
countries, ranging from 8 % of respondents from Japan
to 39 % of respondents from Italy and Spain. Egg donation
was reported as an important unmet need by specialists
from 4 countries: China (26 %), France (48 %), Germany
(18 %), and Italy (17 %). Improved ability to preserve eggs,
embryos, and sperm through freezing was reported as an
unmet need by fertility specialists in China (12 %) and
France (21 %) and improved ability to assess the quality
and viability of an embryo was reported as an unmet need
by specialists in Germany (12 %), Spain (18 %), and the
Table 5 Percentage of patients who received type of ART treatment by patient age group
Proportion of ICSI cycle per age
group (y)
Proportion of fresh embryo cycle per age
group (y)
Proportion of donor cycle per age
group (y)
<35 35 to 39 40 to 42 >42 <35 35 to 39 40 to 42 >42 <35 35 to 39 40 to 42 >42
France n = 29 55 % 55 % 58 % 60 % 65 % 72 % 85 % 92 % 3 % 4 % 7 % 10 %
Germany n = 33 62 % 67 % 71 % 75 % 73 % 76 % 83 % 94 % 0 % 0 % 0 % 0 %
Italy n = 23 80 % 74 % 78 % 86 % 76 % 78 % 87 % 89 % 1 % 2 % 5 % 18 %
Spain n = 38 70 % 77 % 89 % 89 % 71 % 75 % 72 % 68 % 11 % 27 % 49 % 58 %
UK n = 34 48 % 51 % 54 % 56 % 72 % 74 % 83 % 81 % 9 % 12 % 23 % 45 %
US n = 91 68 % 71 % 75 % 76 % 69 % 67 % 69 % 73 % 7 % 11 % 24 % 46 %
China n = 50 35 % 41 % 48 % 51 % 58 % 56 % 48 % 38 % 10 % 10 % 19 % 20 %
Japan n = 65 40 % 45 % 49 % 52 % 39 % 36 % 43 % 46 % 11 % 3 % 2 % 2 %
ART assisted reproductive technology, ICSI intracytoplasmic sperm injection, UK United Kingdom, US United States, Y years
Table 6 Percentage of patients who received single, dual, or more than 2 embryo transfers by patient age group
<35 years old 35 to 39 years old 40 to 42 years old >42 years old
SET DET > DET SET DET > DET SET DET > DET SET DET > DET
France n = 29 54 % 45 % 1 % 39 % 58 % 3 % 19 % 71 % 10 % 15 % 68 % 17 %
Germany n = 33 18 % 80 % 2 % 16 % 74 % 11 % 16 % 67 % 17 % 30 % 53 % 17 %
Italy n = 23 35 % 61 % 4 % 24 % 53 % 23 % 24 % 42 % 34 % 34 % 37 % 30 %
Spain n = 38 46 % 52 % 2 % 35 % 58 % 6 % 39 % 56 % 5 % 55 % 42 % 3 %
UK n = 34 77 % 23 % 0 % 62 % 38 % 0 % 39 % 46 % 14 % 41 % 41 % 18 %
US n = 91 42 % 56 % 1 % 30 % 62 % 8 % 14 % 52 % 33 % 16 % 43 % 41 %
China n = 50 28 % 70 % 3 % 26 % 68 % 6 % 28 % 66 % 6 % 24 % 67 % 9 %
Japan n = 65 91 % 7 % 2 % 86 % 13 % 1 % 69 % 29 % 2 % 71 % 26 % 3 %
DET dual embryo transfer, >DET more than 2 embryos transferred, SET single embryo transfer, UK United Kingdom, US United States
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US (20 %). Other unmet needs also reported included im-
proved access to fertility clinics (14 %) and surrogate preg-
nancy (12 %) by specialists in China and improved
counseling and awareness of fertility issues (8 %) and
genetic testing (6 %) by specialists in Japan.
The future advancements that the fertility specialists
most frequently reported they expect to occur that could
change the field of fertility treatment included improved
embryo selection through imaging and/or metabolomics,
greater use of PGD and PGS, and development of
Fig. 3 Percentage of patients with implantable embryos. Fertility specialists reported the percentage of their patients who had implantable
embryos following an ART procedure. Results are reported by country and by patient age group. ART, assisted reproductive technology; UK,
United Kingdom; US, United States
Fig. 4 Implantation rate by patient age group. Fertility specialists reported the percentage of their patients who had implantation of an embryo
following an ART procedure. Results are reported by country and by patient age group. ART, assisted reproductive technology; UK, United
Kingdom; US, United States
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Fig. 5 Pregnancy rate by patient age group. Fertility specialists reported the percentage of their patients who had a pregnancy following an ART
procedure. Results are reported by country and by patient age group. ART, assisted reproductive technology; UK, United Kingdom; US, United States
Fig. 6 Live birth rate by patient age group. Fertility specialists reported the percentage of their patients who had a live birth outcome following
an ART procedure. Results are reported by country and by patient age group. ART, assisted reproductive technology; UK, United Kingdom; US,
United States
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Fig. 7 Most important improvements in ART fertility treatment within the past 30 years. Fertility specialists reported their perceived most important
improvements in the field of ART fertility treatment within the past 30 years. Results are shown as the percentage of fertility specialists reporting an
improvement by country. The percentages of fertility specialists are shown within the bars. The reporting specialists within a country could overlap
among the improvement categories and total >100 % as specialists were allowed to report >1 important improvements in fertility treatment. ART,
assisted reproductive technology; ICSI, intracytoplasmic sperm injection; PGD, preimplantation genetic diagnosis; SET, single embryo transfer; UK,
United Kingdom; US, United States; V/C, vitrification and cryopreservation
Fig. 8 Greatest unmet needs in current ART fertility treatment. Fertility specialists reported their perceived current greatest unmet needs in the
field of ART fertility treatment. Results are shown as the percentage of fertility specialists reporting an unmet need by country for the top 5
reported unmet needs. The percentages of fertility specialists are shown within the bars. The reporting specialists within a country could overlap
among the unmet needs categories as specialists were allowed to report >1 unmet need in fertility treatment. ART, assisted reproductive technology;
UK, United Kingdom; US, United States
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treatments that improve the implantation rate (Fig. 9).
Fertility preservation through further development of
freezing techniques for gametes was mentioned by
fertility specialists from 5 countries: China (16 %),
France (45 %), Japan (12 %), the UK (21 %), and the
US (16 %). Other expected improvements that were less
frequently reported by the survey respondents were better
hormonal treatments (10 % of respondents in China),
better understanding of the role of the uterus (24 % of
respondents in France and Spain), improvement of fertility
in older patients (23 % of respondents in Japan), improved
embryo quality through gene modification (10 % of re-
spondents in China), and the use of stem cells or somatic
cells to generate gametes (11 % of respondents in Japan).
Discussion
There are several key findings from the current survey
of fertility specialists in 8 countries. There is consensus
among the current survey results, the annual CDC ART
registry report, and the annual ESHRE ART report that
the number of infertility patients seeking fertility treat-
ment is increasing and it is expected that the number of
patients will continue to increase due to aging popula-
tions [15, 16]. The causes of infertility appear to be uni-
versal, with the exception that in China tubal factor was
reported as the most important cause of infertility, as
compared to tubal factor being in the 5th position in the
other countries. As expected, ART outcomes decreased
with increased patient age. There is a strong unmet need
to develop techniques that will help preserve or restore
fertility for older patients. The cost and/or absence of fi-
nancial reimbursement for IVF fertility treatment ap-
pears to be an important barrier to patients’ access to
fertility treatment.
ART outcome was reported to be the most successful
in Spain, the US, and China. These countries also re-
ported that PGD/PGS was one of the most important
fertility treatment improvements in the past year, and
this could potentially explain why these countries have
better outcomes results. However, many other dimen-
sions that have an effect on the outcomes of fertility
treatment should be considered. Thus, the highest suc-
cess rates in Spain, the US, and China cannot be driven
only by the use of PGD/PGS. The number of embryos
transferred, the use of fresh versus frozen embryos, as
well as other environmental and psychological elements
not measured in the current survey can also have an
effect on clinical outcomes. The main unmet need re-
ported by fertility specialists is better coverage for the
cost of IVF. Fertility treatment is a highly technological
field and is very costly, indicating it may be difficult to
address this unmet need. Because ART is not fully
Fig. 9 Anticipated “game changing” developments in ART fertility treatment. Fertility specialists reported their anticipated future “game changing”
developments in ART fertility treatment. Results are shown as the percentage of fertility specialists reporting an anticipated development by
country and the percentages are shown within the bars. The reporting specialists within a country could overlap among the anticipated development
categories because specialists were allowed to report >1 anticipated development within fertility treatment. Embryo selection refers to improved
selection through imaging and/or metabolomics. ART, assisted reproductive technology; PGD/PGS, preimplantation genetic diagnosis/preimplantation
genetic screening; UK, United Kingdom; US, United States
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reimbursed in the studied countries – with the exception
of France – it is up to the leadership of the clinics to
reduce the costs of the procedures.
In terms of future development, the fertility specialists
reported that improved embryo selection and implant-
ation rates are expected to change the field of fertility
treatment. There appears to be little room for improve-
ment in the hormonal treatment used to produce eggs
and several techniques are available to produce embryos,
including IVF, ICSI, IMSI, and donor eggs. With the
advent of time-lapse monitoring of embryo development
and PGD/PGS procedures, embryo selection is one of
the newest areas of development in fertility treatment.
However, these procedures are approved in only a few
countries and have raised some ethical discussions in
most. The factors underlying the implantation rate of
embryos are not well understood, specifically, there is a
need to better understand why good embryos do not
successfully implant. Finally, the survey did not attempt
to find the root causes of infertility in order to move
away from palliating the consequences of infertility and
toward the prevention and best treatment of infertility.
The current study survey results compare favorably
with and further extend the findings within the most
recently reported CDC ART National Summary Report
[16]. The CDC report is based on 456 fertility clinics
within the US, whereas the current study survey
includes only 91 US clinics [16]. The CDC reports ART
efficacy for fresh, non-donor eggs, or embryos compared
with the current study report of all procedures com-
bined. However, fresh, non-donor embryos represent the
majority of procedures in the current study, supporting
the comparability between the reports. The fertility
treatment outcomes data as measured by embryo trans-
fers, PR, and LBR reported in the current survey of
fertility specialists in the US are similar to the CDC
registry report data. The comparison suggests that ART
efficacy is stable, with no shift in fertility treatment
having had an impact on efficacy of treatment, which is
consistent with the lack of any major improvements in
ART procedures since 2012. The comparison of the
current study survey data with the CDC registry report
shows that the number of ICSI procedures has increased
from 68 % reported by the most recent CDC registry
report in 2012 to 73 % reported in 2015 in the current
survey (ranging from 68 % in patients <35 years old to
76 % in patients >42 years old). The reported main
causes of infertility remained the same, with male factor,
ovulatory dysfunction, diminished ovarian reserve, and
both female and male factor being the most common
causes of infertility, as reported by both the CDC regis-
try report examining 2012 data and the current survey.
When comparing the number of embryo transfers with
the CDC 2012 registry data report, there was a trend
toward more frequent use of single embryo transfer in
the current survey.
The comparison of the current study survey results
among European countries, China, and Japan with exist-
ing registry data is more challenging. The ESHRE regis-
try report (2010) is based on 104 fertility clinics in
France, 114 clinics in Germany, 202 clinics in Italy, 103
clinics in Spain, and 72 clinics in the UK [15]. The
current survey report includes 29 fertility clinics in
France, 33 in Germany, 23 in Italy, 38 in Spain and 34 in
the UK. The comparison of outcomes data is compli-
cated because the ESHRE registry reports outcomes data
using a different breakdown in the number of cycles,
presenting ART outcomes results per type of procedure
and per age group; whereas the current study survey
split the data only per age group [15, 17]. The number
of embryos transferred is more easily compared between
the studies, and as was found in comparison with the
CDC 2012 report, a trend was observed toward more
frequent single embryo transfer in the current survey
than in the ESHRE 2010 report. To our knowledge, this
is the first report on fertility treatment in China and
Japan, therefore no comparison of the current survey
results with registry or other data from these countries
is possible.
It should be noted that this research has a number of
limitations. As with any survey, our findings may be
influenced by the recall and response bias of the sur-
veyed individuals. Additionally, only a subset of fertility
specialists participated in our survey, and as with all
analyses, caution should be used when generalizing
results to an entire population. However, the response
rate obtained in our survey is in line with what would be
expected for this type of survey [18]. Regarding the
recruitment of participants, two approaches were used: in
the US, France, Germany, Italy, Spain, and the UK, fertility
specialists were contacted directly by the Deerfield In-
stitute, and were recruited by e-mail or postal mail.
In China and Japan, survey participants were recruited
using a panel provider (i.e., the M3 panel) and were
invited by e-mail. This might include a bias as the M3
panel includes only physicians who accepted to be part of
the panel, while the Deerfield Institute had access to the
full population of fertility specialists. It is important to
note that all respondents answered the same questions
and there was no difference in the questionnaire outside
of translation whether respondents were recruited by the
Deerfield Institute or the M3 panel. Although patient
demographic (e.g., age, smoking, obesity) and biochemical
(e.g., hormonal status) characteristics may play a role in
fertility treatment outcomes, such patient-level data was
outside the scope of the current survey. Future research is
needed to examine the influence of patient-level charac-
teristics as well as the patient assessment and preparation
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protocols used by fertility specialists prior to treat-
ment to ascertain the similarities and differences in
global outcomes.
Conclusions
The survey results provide a unique and comprehensive
interim look at the fertility treatment field ahead of the
next annual release of the ESHRE and CDC ART publi-
cations. The survey results identified a trend toward
more frequent single embryo transfer, most likely due to
improved identification of viable embryos resulting in an
increased chance of pregnancy per embryo transfer. The
survey also highlights differences and similarities among
countries practicing fertility treatment. As reported by
the fertility specialists who participated in the survey,
the key important avenues that are expected to change
in fertility treatment in the future are the improvement
of embryo selection and the improvement of implant-
ation rate.
Abbreviations
ART: assisted reproductive technology; CDC: Centers for Disease Control and
Prevention; DET: dual embryo transfer; >DET: more than 2 embryos
transferred; ESHRE: European Society of Human Reproduction and
Embryology; EU5: European Union Five; ICSI: intracytoplasmic sperm
injection; IMSI: intracytoplasmic morphologically selected sperm injection;
IUI: intrauterine insemination; IVF: in vitro fertilization; LBR: live birth rate;
OI: ovulation induction; PGD: preimplantation genetic diagnosis;
PGS: preimplantation genetic screening; PR: pregnancy rate; SET: single
embryo transfer; V/C: vitrification and cryopreservation; UK: United Kingdom;
US: United States.
Competing interests
CA: Is an employee of Deerfield Institute.
DG: Is an employee of Deerfield Institute.
Authors’ contributions
Made substantial contributions to conception and design or acquisition of
data: CA + DG. Made substantial contribution to analysis and interpretation
of data: CA + DG. Involved in drafting the manuscript or revising it critically
for important intellectual content: CA + DG. Gave final approval of the
version to be published: CA. Agrees to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any
part of the work are appropriately investigated and resolved: CA.
Acknowledgments and funding disclosures
The authors wish to thank Lynanne McGuire, PhD, of MedVal Scientific
Information Services, LLC, for providing medical writing and editorial
assistance, which was funded by Deerfield Institute. This manuscript was
prepared according to the International Society for Medical Publication
Professionals’ “Good Publication Practice for Communicating Company-
Sponsored Medical Research: the GPP2 Guidelines”.
Author details
1Deerfield Institute, Route de la Corniche 3a, 1066 Epalinges, Switzerland.
2Deerfield Institute, New York, USA.
Received: 28 October 2015 Accepted: 3 December 2015
References
1. Cohen J, Trounson A, Dawson K, Jones H, Hazekamp J, Nygren KG, et al.
The early days of IVF outside the UK. Hum Reprod Update. 2005;11:439–59.
2. Wang J, Sauer MV. In vitro fertilization (IVF): a review of 3 decades of
clinical innovation and technological advancement. Ther Clin Risk
Manag. 2006;2:355–64.
3. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final
oocyte maturation: time for a change of practice? Hum Reprod Update.
2011;17:510–24.
4. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC.
Increased live birth rates with GnRH agonist addition for luteal support in
ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update.
2011;17:734–40.
5. Fauser BC, Nargund G, Andersen AN, Norman R, Tarlatzis B, Boivin J, et al. Mild
ovarian stimulation for IVF: 10 years later. Hum Reprod. 2010;25:2678–84.
6. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation
and probability of pregnancy after IVF: a systematic review and meta-
analysis of over 60 000 cycles. Hum Reprod Update. 2013;19:433–57.
7. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P,
et al. Added value of ovarian reserve testing on patient characteristics in
the prediction of ovarian response and ongoing pregnancy: an individual
patient data approach. Hum Reprod Update.
2013;19:26–36.
8. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in
IVF using ovarian reserve markers: from theory to practice. Hum Reprod
Update. 2014;20:124–40.
9. Zhang XD, Liu JX, Liu WW, Gao Y, Han W, Xiong S, et al. Time of
insemination culture and outcomes of in vitro fertilization: a systematic
review and meta-analysis. Hum Reprod Update. 2013;19:685–95.
10. Evans J, Hannan NJ, Edgell TA, Vollenhoven BJ, Lutjen PJ, Osianlis T, et al.
Fresh versus frozen embryo transfer: backing clinical decisions with scientific
and clinical evidence. Hum Reprod Update. 2014;20:808–21.
11. Zhao J, Zhang Q, Li Y. The effect of endometrial thickness and pattern
measured by ultrasonography on pregnancy outcomes during IVF-ET cycles.
Reprod Biol Endocrinol. 2012;10:100.
12. Dar S, Lazer T, Shah PS, Librach CL. Neonatal outcomes among singleton
births after blastocyst versus cleavage stage embryo transfer: a systematic
review and meta-analysis. Hum Reprod Update. 2014;20:439–48.
13. Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A. Embryo
incubation and selection in a time-lapse monitoring system improves
pregnancy outcome compared with a standard incubator: a retrospective
cohort study. Fertil Steril. 2012;98:1481–9.
14. Fragouli E, Lalioti MD, Wells D. The transcriptome of follicular cells:
biological insights and clinical implications for the treatment of infertility.
Hum Reprod Update. 2014;20:1–11.
15. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D' Hooghe T, Castilla JA, et al.
Assisted reproductive technology in Europe, 2010: results generated from
European registers by ESHRE†. Hum Reprod. 2014;29:2099–113.
16. Centers for Disease Control and Prevention, American Society for
Reproductive Medicine, Society for Assisted Reproductive Technology.
2012 Assisted Reproductive Technology National Summary Report. Atlanta,
GA: US Dept of Health and Human Services; 2014.
17. European Society of Human Reproduction and Embryology. Supplementary
data: participating centers. Hum Reprod. 2014;0:1–33.
18. Kohut A, Keeter S, Doherty C, Dimock M, Christian L. Assessing the
representativeness of public opinion surveys. Washington, D.C: The Pew
Research Center for the People & the Press; 2012.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Audibert and Glass Reproductive Biology and Endocrinology  (2015) 13:133 Page 13 of 13
